Mesenchymal Cell News Volume 7.41 | Oct 20 2015

RECK (Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs) Regulates Migration, Differentiation and Wnt/β-Catenin Signaling in Human Mesenchymal Stem Cells
Knockdown of RECK in human mesenchymal stem cells (hMSCs) promoted monolayer regeneration and chemotactic migration of hMSCs, as demonstrated by scratch wound and chemotaxis assay analyses. Moreover, expression of endogenous RECK was upregulated upon osteogenic differentiation and diminished after adipogenic differentiation of hMSCs. [Cell Mol Life Sci] Abstract

A Regulatory Loop Containing miR-26a, GSK3β and C/EBPα Regulates the Osteogenesis of Human Adipose-Derived Mesenchymal Stem Cells
Scientists analyzed the role of miR-26a in the regulation of human adipose-derived mesenchymal stem cell (hADSC) osteogenesis. The endogenous expression of miR-26a increased during the osteogenic differentiation. The overexpression of miR-26a promoted hADSC osteogenesis, whereas osteogenesis was repressed by miR-26a knockdown. [Sci Rep] Full Article

Estrogen Secreted by Mesenchymal Stem Cells Necessarily Determines Their Feasibility of Therapeutical Application
In vitro experiments showed that bone marrow-derived mesenchymal stem cells (BMSCs) cultured from C57BL/6J mice secreted estrogen (E2) in a time-dependent manner. In vivo studies identified a significantly increased E2 level in serum after a single administration of BMSCs, and a sustained elevation of E2 level upon a repetitive administration. [Sci Rep] Full Article

Mesenchymal Stem Cells Suppress Neuronal Apoptosis and Decrease IL-10 Release via the TLR2/NFκB Pathway in Rats with Hypoxic-Ischemic Brain Damage
Researchers studied the mechanisms by which mesenchymal stem cells mediate immunomodulation via the key effectors Toll-like receptor 2 (TLR2) and interleukin-10 (IL-10). [Mol Brain] Full Article

Protease Inhibitors Enhance Extracellular Collagen Fibril Deposition in Human Mesenchymal Stem Cells
The authors investigated the fate of collagen when it is in contact with mesenchymal stem cells and hypothesized that protease inhibition would enhance their extracellular deposition of collagen fibrils. [Stem Cell Res Ther] Full Article

Macrophages Derived from THP-1 Promote the Osteogenic Differentiation of Mesenchymal Stem Cells through the IL-23/IL-23R/β-Catenin Pathway
Researchers investigated the stimulatory effects of THP-1 macrophage conditioned medium on the osteogenic differentiation of human mesenchymal stem cells (MSCs) and the associated signaling pathways. The osteogenic differentiation of MSCs was induced after exposure to osteogenic differentiation medium. [Exp Cell Res] Abstract

MiR-455-3p Regulates Early Chondrogenic Differentiation via Inhibiting Runx2
Investigators showed that miR-455-3p is increased in ATDC5 cells from 0 days to 21 days, but rapidly decreases at 28 days, and a similar expression kinetic is detected in the development of mouse embryos. They showed that miR-455-3p functions as an activator for early chondrogenic differentiation, most likely by inhibiting the expression of Runt-related transcription factor 2 (Runx2) as indicated by luciferase reporter assays. [FEBS Lett] Abstract

Osteogenic Profile of Mesenchymal Cell Populations Contributing to Alveolar Bone Formation
The authors investigated the osteogenic profile of mesenchymal cells dissected from mouse mandible slices at the stage of early alveolar bone formation. [Cells Tissues Organs] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Celgene and Mesoblast Extend Agreement
Mesoblast Limited announced that it has agreed with Celgene Corporation to extend for a period of six months Celgene’s right of first refusal with respect to Mesoblast’s proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease, certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection. [Mesoblast Limited (GlobeNewswire, Inc.)] Press Release

MAX BioPharma Announces Key Updates on Its Oxysterol Therapeutics™ Development Program, Intellectual Property Portfolio and Funding Initiatives
MAX BioPharma, Inc. announced that it has successfully demonstrated potent osteogenic activity as well as tissue selectivity of its proprietary small molecule oxysterols that are bone-targeted. [MAX BioPharma, Inc. (PR Newswire Association LLC)] Press Release

BrainStorm Strengthens Intellectual Property Position – Granted Patent for Company’s NurOwn^® Technology Platform
BrainStorm Cell Therapeutics Inc. announced that the company has been granted a patent by the Israeli Patent Office for BrainStorm’s application, titled Isolated Population of Cells, Methods of Generating Same, and Uses Thereof in the Treatment of CNS Diseases. The granted claims include neurotrophic factor-secreting cells derived from mesenchymal stem cells, methods for producing those cells and methods of using those cells for the treatment of neurologic diseases. [BrainStorm Cell Therapeutics Inc. (PR Newswire Association LLC)] Press Release

From our sponsor: 3D intestinal organoid culture is made easy with IntestiCult™. Request a sample.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mesenchymal cell community.

Postdoctoral Position – Stem Cell Biology (Odense University Hospital)

Postdoctoral Position – Bone Research (Weill Cornell College of Medicine)

Postdoctoral Position – Stem Cell Research (Karolinska Institute)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Faculty Position – Life Sciences (Stowers Institute for Medical Research)

Faculty Positions – Stem Cells and Regenerative Medicine (King Abdullah University of Science and Technology)

Postdoctoral Fellow – Cardiovascular Stem Cell Biology and Tissue Engineering (Yale University)

Junior Group Leader – Cell and Development Biology Program (Centre for Genomic Regulation)

Postdoctoral Fellow/Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.